Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D M Finkelstein

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Biometrics|September 14, 2000
Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank testsJ M Robins, D M Finkelstein
Biometrics|September 14, 2000
A proportional hazards model for multivariate interval-censored failure time dataW B Goggins, D M Finkelstein
Biometrics|December 1, 1985
A semiparametric model for regression analysis of interval-censored failure time dataD M Finkelstein, R A Wolfe
Biometrics|March 1, 1989
Analysis of multiple tumor data from a rodent carcinogenicity experimentD M Finkelstein, D A Schoenfeld
The Journal of Otolaryngology|December 1, 1992
Evaluation and management of the drooling patientD M Finkelstein, W S Crysdale
Cancer|March 10, 2001
Evidence for an association between cutaneous melanoma and non-Hodgkin lymphomaW B Goggins, D M Finkelstein, H Tsao
Statistics in Medicine|April 30, 1997
Analysis of multiple failure time data from an AIDS clinical trialD M Finkelstein, D A Schoenfeld, E Stamenovic
Biometrics|April 25, 2001
Applying the Cox proportional hazards model when the change time of a binary time-varying covariate is interval censoredW B Goggins, D M Finkelstein, A M Zaslavsky
American Journal of Public Health|August 1, 1987
Prevalence of hepatitis B serologic markers in community hospital personnelA A McLean, G R Monahan, D M Finkelstein
AIDS (London, England)|July 1, 1993
Designing phase II studies of chemotherapy for HIV infection using CD4 as an end-pointD A Schoenfeld, D M Finkelstein, D D Richman
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Biometrics|September 14, 2000
Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank testsJ M Robins, D M Finkelstein
Biometrics|September 14, 2000
A proportional hazards model for multivariate interval-censored failure time dataW B Goggins, D M Finkelstein
Biometrics|December 1, 1985
A semiparametric model for regression analysis of interval-censored failure time dataD M Finkelstein, R A Wolfe
Biometrics|March 1, 1989
Analysis of multiple tumor data from a rodent carcinogenicity experimentD M Finkelstein, D A Schoenfeld
The Journal of Otolaryngology|December 1, 1992
Evaluation and management of the drooling patientD M Finkelstein, W S Crysdale
Cancer|March 10, 2001
Evidence for an association between cutaneous melanoma and non-Hodgkin lymphomaW B Goggins, D M Finkelstein, H Tsao
Statistics in Medicine|April 30, 1997
Analysis of multiple failure time data from an AIDS clinical trialD M Finkelstein, D A Schoenfeld, E Stamenovic
Biometrics|April 25, 2001
Applying the Cox proportional hazards model when the change time of a binary time-varying covariate is interval censoredW B Goggins, D M Finkelstein, A M Zaslavsky
American Journal of Public Health|August 1, 1987
Prevalence of hepatitis B serologic markers in community hospital personnelA A McLean, G R Monahan, D M Finkelstein
AIDS (London, England)|July 1, 1993
Designing phase II studies of chemotherapy for HIV infection using CD4 as an end-pointD A Schoenfeld, D M Finkelstein, D D Richman
Pageof 9